| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 12/13/2001 | CA2411564A1 Method of treating pain using nalbuphine and opioid antagonists |
| 12/13/2001 | CA2411542A1 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | CA2411536A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | CA2411473A1 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | CA2411432A1 A method of treatment of alzheimer's disease with a protein extractable from mammalian organs |
| 12/13/2001 | CA2411430A1 A method of treatment of parkinson's disease with a protein extractable from mammalian organs |
| 12/13/2001 | CA2411429A1 A method of treatment of huntington's chorea with a protein extractable from mammalian organs |
| 12/13/2001 | CA2411428A1 A method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs |
| 12/13/2001 | CA2411351A1 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors |
| 12/13/2001 | CA2411069A1 The human voltage gated sodium channel .beta.-1a subunit and methods of use |
| 12/13/2001 | CA2411062A1 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | CA2410188A1 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 12/13/2001 | CA2409392A1 Intracellular signaling proteins |
| 12/13/2001 | CA2409268A1 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | CA2409015A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | CA2408748A1 Nuclear hormone receptor |
| 12/13/2001 | CA2407164A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
| 12/13/2001 | CA2398277A1 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for protecting cns cells from glutamate toxicity |
| 12/12/2001 | EP1162265A2 Human PEM as a target for fertility control and Alzheimer therapy |
| 12/12/2001 | EP1161948A2 Pharmaceutical or food composition for treatment of brain edema |
| 12/12/2001 | EP1161549A2 Retrovirus producing cells utilizing a high multiplicity of transduction |
| 12/12/2001 | EP1161534A1 Differential expression of organellar gene products |
| 12/12/2001 | EP1161525A2 Methods and compositions for regulating memory consolidation |
| 12/12/2001 | EP1161524A2 CELLS COEXPRESSING AN AMYLOID PRECURSOR PROTEIN AND AN $g(a)-SECRETASE AND THEIR USES IN TEST METHODS AND DIAGNOSTICS |
| 12/12/2001 | EP1161523A1 Cells, cell populations, and methods of making and using same |
| 12/12/2001 | EP1161521A2 Transplantation of haematopoietic cells |
| 12/12/2001 | EP1161449A1 Modulators of beta-amyloid peptide aggregation comprising d-amino acids |
| 12/12/2001 | EP1161448A1 49 human secreted proteins |
| 12/12/2001 | EP1161447A1 50 human secreted proteins |
| 12/12/2001 | EP1161444A1 A novel inhibitor of programmed cell death |
| 12/12/2001 | EP1161442A2 Exocytosis pathway proteins and methods of use |
| 12/12/2001 | EP1161441A1 Compositions for promoting nerve regeneration |
| 12/12/2001 | EP1161434A1 Pyridopyranoazepine derivatives, preparation and therapeutic use |
| 12/12/2001 | EP1161431A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 12/12/2001 | EP1161429A2 Heterocyclic compounds as adenosine deaminase inhibitors |
| 12/12/2001 | EP1161419A1 Spirocyclic ketones and their use as tachykinin antagonists |
| 12/12/2001 | EP1161418A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors |
| 12/12/2001 | EP1161415A2 N-cyanomethylamides as protease inhibitors |
| 12/12/2001 | EP1161260A1 Tumor necrosis factor antagonists for the treatment of neurological disorders |
| 12/12/2001 | EP1161252A1 Use of extracts from ginkgo biloba leaves for treating sleep disorders |
| 12/12/2001 | EP1161244A2 Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine |
| 12/12/2001 | EP1161243A2 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
| 12/12/2001 | EP1161239A2 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis |
| 12/12/2001 | EP1161238A1 Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist |
| 12/12/2001 | EP1161233A2 Lxr modulators |
| 12/12/2001 | EP1161232A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists |
| 12/12/2001 | EP1161228A2 Composition comprising isoquercetin and ascorbic acid in a sustained release form |
| 12/12/2001 | EP1161226A1 Phosphocholine linked prodrug derivatives |
| 12/12/2001 | EP1077688B1 Transdermal therapeutic system containing pergolide |
| 12/12/2001 | EP0983266B1 novel tetrahydroisoquinolin thiophenecarboximidamides |
| 12/12/2001 | EP0938471B1 The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 12/12/2001 | EP0889730B1 Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| 12/12/2001 | EP0888285B1 Novel bridged cyclic amino acids as pharmaceutical agents |
| 12/12/2001 | EP0861248B1 Indolealkyl derivatives of benzodioxanmethylamine as 5-ht1a receptor ligands |
| 12/12/2001 | EP0809656B1 MONOCLONAL ANTIBODY SPECIFIC FOR beta-A4 PEPTIDE |
| 12/12/2001 | EP0785788B1 Use of cck-b receptor antagonists for the treatment of sleep disorders |
| 12/12/2001 | EP0772597B1 3,4-substituted pyrazoles for the treatment of inflammation |
| 12/12/2001 | EP0760665B1 Compositions containing 5htia and 5htid antagonists |
| 12/12/2001 | EP0716602B1 The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases |
| 12/12/2001 | EP0663912B1 Heterocyclic ether compounds that enhance cognitive function |
| 12/12/2001 | EP0651789B1 Method for preventing zoster and alleviating varicella related post-herpetic neuralgia |
| 12/12/2001 | EP0522091B1 Use of a mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis |
| 12/12/2001 | CN1326458A CRF receptor antagonists and methods relating thereto |
| 12/12/2001 | CN1326456A 8-Azabicyclo [3.,2.1] Oct-2-Ene and-Octane derivatives |
| 12/12/2001 | CN1326450A Hydroxyflavone derivatives as tau protein kinase inhibitors |
| 12/12/2001 | CN1326443A Fluorinated 3,4-dihydroquinoline derivatives used as NOS inhibitors |
| 12/12/2001 | CN1326360A Use of enterobacterium protein OMPA for specific targeting towards antigen-presening cells |
| 12/12/2001 | CN1326351A Use of certain drugs for treating nerve root injury |
| 12/12/2001 | CN1326348A Riluzole and alpha-tocopherol combination |
| 12/12/2001 | CN1326344A PUFA supplements |
| 12/12/2001 | CN1326342A Treatment of addition and addiction-related behavior |
| 12/12/2001 | CN1326340A Pharmaceutical composition for treatment of acute disorders |
| 12/12/2001 | CN1325730A Application of alkaline fibroblast growth factor in preparing medicine to prevent and cure cerebral injury |
| 12/12/2001 | CN1325705A Anti-areola sweets and preparing process thereof |
| 12/12/2001 | CN1076020C Novel polymorphs of lesopitron dichlorohydrate and its hydrated forms, preparation method and compositions |
| 12/12/2001 | CN1076016C O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same |
| 12/11/2001 | US6329566 Methods for the detection, treatment, and prevention of neurodegeneration |
| 12/11/2001 | US6329539 Prostagladin derivatives |
| 12/11/2001 | US6329520 Used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases or in determining doses of therapeutic agents that occupy many receptors |
| 12/11/2001 | US6329499 Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
| 12/11/2001 | US6329449 Pulverulent rubber powders comprising modified fillers, processes for their preparation and their use |
| 12/11/2001 | US6329421 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| 12/11/2001 | US6329418 Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| 12/11/2001 | US6329415 Aromatic heterocyclic compounds as antiinflammatory agents |
| 12/11/2001 | US6329401 Enhancement of sleep with a tachykinin antagonist |
| 12/11/2001 | US6329397 Hydroxy pipecolate hydroxamic acid derivatives |
| 12/11/2001 | US6329390 5-Bicycloindole compounds |
| 12/11/2001 | US6329385 Antiinflammatory agents, antiarthritic agents, viral diseases and gastrointestinal disorders |
| 12/11/2001 | US6329373 Metalloproteinase inhibitors |
| 12/11/2001 | US6329366 Heterocyclic, piperidine, indole derivitives for treatment of nervous system disorders and serotonin antagonist |
| 12/11/2001 | US6329365 Inhibitors of interleukin-1β converting enzyme |
| 12/11/2001 | US6329344 Urea derivative of alkylene dioxyfuran ethers |
| 12/11/2001 | US6328999 Ginkgo biloba leaf extracts with a reduced 4′-O-methylpyridoxine and biflavone content |
| 12/11/2001 | US6328708 Device for controlled anaesthesia, analgesia and /or sedation |
| 12/11/2001 | CA2226292C Substituted benzolactam compounds as substance p antagonists |
| 12/11/2001 | CA2117953C Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| 12/11/2001 | CA2053709C Piperazine derivatives |
| 12/06/2001 | WO2001092892A2 Methods to identify compounds that modulate rage |
| 12/06/2001 | WO2001092530A1 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |